- IBIO Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
CORRESP Filing
iBio (IBIO) CORRESPCorrespondence with SEC
Filed: 30 Nov 23, 12:00am
November 30, 2023
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tamika Sheppard
Re: | iBio, Inc. | ||
Registration Statement on Form S-1 | |||
Filed October 27, 2023 File No: 333-275204 |
Dear Ms. Sheppard:
iBio, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-275204), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Monday, December 4, 2023, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Very truly yours, | |||
IBIO, INC. | |||
By: | /s/ Felipe Duran | ||
Name: | Felipe Duran | ||
Title: | Chief Financial Officer |
cc: Leslie Marlow, Blank Rome LLP